RPRX [NASD]
Royalty Pharma plc
Index- P/E40.06 EPS (ttm)1.00 Insider Own0.20% Shs Outstand433.96M Perf Week0.55%
Market Cap23.65B Forward P/E11.81 EPS next Y3.38 Insider Trans-41.65% Shs Float195.99M Perf Month-5.89%
Income602.40M PEG3.58 EPS next Q0.80 Inst Own63.20% Short Float3.76% Perf Quarter0.20%
Sales2.28B P/S10.38 EPS this Y13.30% Inst Trans0.41% Short Ratio3.57 Perf Half Y-0.62%
Book/sh13.31 P/B3.00 EPS next Y12.81% ROA3.50% Target Price52.00 Perf Year-1.94%
Cash/sh4.92 P/C8.12 EPS next 5Y11.20% ROE10.40% 52W Range34.86 - 47.10 Perf YTD0.23%
Dividend0.76 P/FCF- EPS past 5Y- ROI11.10% 52W High-15.35% Beta-
Dividend %1.90% Quick Ratio22.00 Sales past 5Y- Gross Margin- 52W Low14.37% ATR1.32
Employees66 Current Ratio22.00 Sales Q/Q-1.90% Oper. Margin62.40% RSI (14)45.60 Volatility3.78% 2.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.10% Profit Margin26.40% Rel Volume0.52 Prev Close39.94
ShortableYes LT Debt/Eq1.23 EarningsMay 05 BMO Payout48.20% Avg Volume2.07M Price39.87
Recom2.10 SMA20-4.30% SMA50-1.12% SMA2001.74% Volume315,234 Change-0.18%
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Jul-13-20Initiated UBS Neutral $52
Jul-13-20Initiated SunTrust Buy $56
Jul-13-20Initiated Morgan Stanley Equal-Weight $51
Jul-13-20Initiated JP Morgan Neutral $50
Jul-13-20Initiated Goldman Neutral $47
Jul-13-20Initiated Cowen Outperform $55
Jul-13-20Initiated Citigroup Neutral $50
Jul-13-20Initiated BofA Securities Buy $55
May-05-22 07:00AM  
May-04-22 03:32PM  
Apr-18-22 08:00AM  
Apr-13-22 08:00AM  
Mar-29-22 08:00AM  
Mar-15-22 09:48AM  
Mar-03-22 08:30AM  
Mar-01-22 03:34AM  
Feb-25-22 09:01PM  
Feb-16-22 08:15AM  
Feb-15-22 07:00AM  
Feb-08-22 01:38PM  
Feb-07-22 01:38PM  
12:03PM  
Feb-04-22 05:38PM  
03:11PM  
Jan-31-22 01:38PM  
Jan-27-22 01:38PM  
Jan-20-22 07:45AM  
Jan-18-22 02:57PM  
Jan-14-22 07:05AM  
Jan-10-22 07:00AM  
Jan-07-22 08:07AM  
07:30AM  
Jan-06-22 08:30AM  
Jan-05-22 04:15PM  
Dec-27-21 02:54PM  
Dec-16-21 09:38AM  
Dec-06-21 11:00AM  
Nov-29-21 04:15PM  
Nov-23-21 07:21AM  
Nov-22-21 07:10AM  
Nov-19-21 06:46PM  
Nov-10-21 07:00AM  
Nov-09-21 11:16PM  
Oct-18-21 09:00AM  
Oct-15-21 09:00AM  
Oct-11-21 09:18AM  
Sep-29-21 11:48AM  
Sep-03-21 09:00AM  
Aug-11-21 07:00AM  
Jul-29-21 07:02AM  
Jul-19-21 09:00AM  
Jul-16-21 09:00AM  
Jul-15-21 04:54PM  
Jul-13-21 10:41AM  
Jul-05-21 05:30AM  
Jun-07-21 09:00AM  
Jun-02-21 07:40AM  
May-18-21 08:49AM  
May-11-21 08:00PM  
07:00AM  
05:45AM  
May-07-21 09:00AM  
Apr-21-21 04:15PM  
08:10AM  
Apr-15-21 09:00AM  
Apr-08-21 07:40AM  
07:30AM  
Apr-01-21 07:30AM  
Mar-30-21 08:00AM  
Mar-11-21 02:37PM  
Feb-17-21 12:30PM  
07:00AM  
05:45AM  
Feb-15-21 05:30AM  
Jan-29-21 11:35PM  
Jan-22-21 08:00AM  
Jan-19-21 08:30AM  
08:00AM  
Jan-08-21 08:05AM  
08:00AM  
Jan-07-21 04:15PM  
Dec-23-20 03:16PM  
Dec-22-20 08:30AM  
Dec-21-20 08:12AM  
Dec-17-20 04:29PM  
Dec-07-20 08:45AM  
08:40AM  
Dec-04-20 04:31PM  
Nov-16-20 03:39AM  
Nov-10-20 05:40PM  
Nov-02-20 07:30AM  
Oct-20-20 04:32PM  
Oct-19-20 09:00AM  
Oct-15-20 11:45PM  
09:15AM  
Oct-13-20 04:10PM  
Oct-02-20 07:00AM  
Sep-16-20 11:42AM  
Sep-02-20 04:25PM  
08:00AM  
Aug-25-20 08:14AM  
08:00AM  
Aug-19-20 09:00AM  
Aug-12-20 07:00AM  
Aug-07-20 09:40AM  
Aug-03-20 04:15PM  
Jul-20-20 04:15PM  
07:45AM  
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RIGGS RORY BDirectorMar 29Sale38.5960,0002,315,322601,712Mar 30 06:46 PM
RIGGS RORY BDirectorMar 21Sale39.0539,8671,556,8460Mar 21 06:20 PM
RIGGS RORY BDirectorMar 18Sale39.55129,2225,110,67514,322Mar 21 06:20 PM
Fernandez Henry ADirectorFeb 24Buy37.4932,5001,218,37358,200Feb 25 07:21 PM
RIGGS RORY BDirectorDec 29Sale40.0075,0003,000,352592,748Dec 30 06:07 PM
RIGGS RORY BDirectorDec 28Sale40.21109,4484,400,415301,974Dec 30 06:07 PM
RIGGS RORY BDirectorNov 17Sale42.34139,3895,902,285500,549Nov 18 07:15 PM
RIGGS RORY BDirectorNov 17Sale42.3962,4352,646,401622,398Nov 18 07:15 PM
Lloyd George W.EVP, Investments & GCNov 17Sale42.3984,1483,566,832630,000Nov 18 07:18 PM
Lloyd George W.EVP, Investments & GCNov 16Sale42.39165,8527,029,862495,860Nov 18 07:18 PM
RIGGS RORY BDirectorNov 16Sale42.0112,565527,805684,833Nov 18 07:15 PM
RIGGS RORY BDirectorSep 29Sale36.3563,7772,318,494899,306Sep 30 03:56 PM
RIGGS RORY BDirectorSep 29Sale36.5024,648899,706615,112Sep 30 03:56 PM
RIGGS RORY BDirectorSep 28Sale36.7540,0001,470,088639,760Sep 30 03:56 PM
Lloyd George W.EVP, Investments & GCJul 26Sale39.7813,362531,532595,860Jul 27 05:29 PM
Reddoch James F.EVP, Research & InvestmentsJul 26Sale39.788,949355,9771,170,800Jul 27 05:25 PM
Reddoch James F.EVP, Research & InvestmentsJul 26Sale39.788,949355,9771,170,800Jul 27 05:23 PM
Reddoch James F.EVP, Research & InvestmentsJul 14Sale42.002841,179,749Jul 14 05:17 PM
Reddoch James F.EVP, Research & InvestmentsJul 13Sale42.0117,832749,0811,179,751Jul 14 05:17 PM
Lloyd George W.EVP, Investments & GCJul 13Sale42.0123,049968,252600,773Jul 14 05:18 PM
Lloyd George W.EVP, Investments & GCJul 12Sale42.041004,204806,430Jul 14 05:18 PM
Reddoch James F.EVP, Research & InvestmentsJul 12Sale42.041004,2041,197,583Jul 14 05:17 PM
Lloyd George W.EVP, Investments & GCJul 08Sale42.0549,0592,062,789605,841Jul 08 07:36 PM
Reddoch James F.EVP, Research & InvestmentsJul 08Sale42.0540,6551,709,3801,197,683Jul 08 07:37 PM
Reddoch James F.EVP, Research & InvestmentsJul 07Sale42.012,19292,0871,238,338Jul 08 07:37 PM
Lloyd George W.EVP, Investments & GCJul 07Sale42.012,900121,828614,233Jul 08 07:36 PM
Lloyd George W.EVP, Investments & GCJul 06Sale42.4136,5301,549,145614,633Jul 08 07:36 PM
Reddoch James F.EVP, Research & InvestmentsJul 06Sale42.4030,2701,283,5601,240,530Jul 08 07:37 PM
RIGGS RORY BDirectorJun 29Sale41.26481,00019,844,8463,451,258Jun 29 08:31 PM
RIGGS RORY BDirectorJun 28Sale42.11167,4487,051,2693,932,258Jun 29 08:31 PM
RIGGS RORY BDirectorJun 25Sale42.72666,46428,474,019933,910Jun 29 08:31 PM
Lloyd George W.EVP, Investments & GCJun 10Sale46.4970,0003,254,369240,000Jun 14 06:42 PM
Lloyd George W.EVP, Investments & GCJun 08Sale46.4870,0003,253,631250,000Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 08Sale46.4350,0002,321,5401,270,800Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 07Sale46.5950,0002,329,4191,320,800Jun 08 08:12 PM
Lloyd George W.EVP, Investments & GCJun 07Sale46.34122,5005,676,228260,000Jun 08 08:12 PM
Urist MarshallEVP & Co-Head of R&IJun 07Sale47.0216,568779,0590Jun 08 08:15 PM
Urist MarshallEVP & Co-Head of R&IJun 04Sale45.1316,566747,66216,568Jun 08 08:15 PM
Lloyd George W.EVP, Investments & GCJun 04Sale44.7860,0002,686,938280,000Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 04Sale44.60100,0004,459,7301,370,800Jun 08 08:12 PM
Urist MarshallEVP & Co-Head Research & Inv.Jun 02Sale41.5214,566604,85033,134Jun 04 06:52 PM
Reddoch James F.EVP, Research & InvestmentsJun 02Sale42.1350,0002,106,5601,470,800Jun 04 06:50 PM